STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

PT-141 nasal research (bremelanotide routes)

Also known as

PT-141 nasal research · bremelanotide nasal · PT-141 nasal spray · intranasal PT-141 · intranasal bremelanotide · PT141 nose spray · PT-141 IN · bremelanotide intranasal spray · compounded PT-141 spray · nasal Vyleesi (misnomer)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Niche talk Systemic Intranasal Libido & melanocortin

Systemic CNS melanocortin (MC3R/MC4R) desire/arousal path — nasal is a delivery route debate, not a local genital drug.

What people say This card covers intranasal bremelanotide/PT-141: the same melanocortin agonist as injectable Vyleesi, but a different delivery history. Historical controlled nasal formulations used much larger milligram amounts than many modern compounded sprays, so the two cannot be treated as bioequivalent. Doses people talk about
Modern positive reportNominal 1.25 mg total intranasal

The user described three sprays in each nostril, warmth and sexual response within about 10 minutes, fading after roughly 20 minutes; another commenter questioned whether the stated bottle concentration could deliver that mass.

Modern non-responseNominal 2 mg total intranasal

A different commenter described one 1 mg-labeled spray in each nostril and no felt effect; actual delivered mass and product identity were not independently verified.

Historical controlled rangeAbout 4–20 mg IN

Early male studies used controlled study formulations; significant erectile response was reported above 7 mg. This does not establish a modern compounded-spray amount.

Historical sildenafil-failure study10 mg IN

The randomized study enrolled sildenafil nonresponders, but a 2023 expression of concern now limits confidence in its results and methods.

Spray concentration, actuation and product identity were not verified in the community reports. Historical and modern formulations are not interchangeable, and the 10 mg sildenafil-failure paper carries an expression of concern.

Half-life & effect duration

Half-life in the body
  • Nasal · early studyAbout 1.85–2.09 hours
  • Vyleesi injection · comparisonAbout 2.7 hours; range 1.9–4 hours
Felt duration people report
  • One nasal accountStarted within 10 minutes; lasted about 20 minutes
  • Older community duration reportsAbout 1–4 hours
  • Another nasal accountStarted around 30–45 minutes, without nausea
  • Other accountNo effect
Timing context & sources
How it may feel Modern reports conflict: one user claimed warmth, relaxation and sexual response within 10 minutes after a nominal 1.25 mg, fading around 20 minutes; another reported nothing at a nominal 2 mg; a separate user described 30–45-minute onset and no nausea after injections had caused nausea.
Cycles people discuss Use is discussed as event-tied and intermittent, not a loading cycle. Frequency ceilings borrowed from the SC label do not validate a nasal regimen, especially when modern spray concentration and absorbed exposure are uncertain. Timing Nasal discussions often allow 30–60+ minutes before activity, but congestion, drip and uneven spray delivery can alter the experience. Event planning and nausea or irritation drive timing; this is not a validated nasal schedule. Stacks Sildenafil or tadalafil is the clearest adjacent class because central melanocortin signaling and peripheral PDE5 blood-flow effects differ. Historical combination findings belong to specified trial formulations; modern mixed products and anti-nausea co-use complicate attribution and safety. Watch for Why nasal BP history matters: Increases in blood pressure in some nasally dosed patients, coupled with plasma-level variability, drove FDA-era clinical holds and sponsor discontinuation of nasal as first-line sexual-dysfunction therapy (~2007–2008).
Related
PT-141Kisspeptin-10Oxytocin

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

An early controlled male intranasal study reported mean parent half-life of 1.85–2.09 hours and median Tmax of 0.5 hour.

In healthy men, Cmax and AUC rose dose-dependently in the historical study formulation. Across the healthy-subject and separate ED studies, erectile response was significant versus placebo above 7 mg with first erection around 30 minutes.

Historical study formulations and male populations do not establish bioequivalence, delivered mass or safety for present-day compounded or gray-market sprays; this is not the SC Vyleesi PK value.

Felt duration people report

Modern reports include a rapid response lasting about 20 minutes, a separate 30–45-minute onset report without nausea, and complete non-response; no stable felt window is established.

One 1.25 mg-claimed report described onset within 10 minutes and about 20 minutes of effect, while a 2 mg-labeled commenter felt nothing. A separate route-comparison user reported 30–45-minute nasal onset without injection-like nausea but gave no nasal amount.

Nominal spray amounts were not assayed, one concentration was challenged in-thread, products and actuation differed, and anonymous unblinded reports cannot establish a stable felt clock or route conversion.

  • Reddit r/pt141info — Interesting experience with PT-141 nasal spray (opens in a new tab)Opening account claimed 1.25 mg total across six sprays with warmth and sexual response within 10 minutes, fading after about 20 minutes; a reply challenged concentration plausibility, and a later user reported no effect from two 1 mg-labeled sprays.Anonymous unblinded reports, internally disputed dose calibration, no product assay, no standardized endpoint and distinct authors; nominal milligrams may not equal delivered or absorbed mass.
  • Reddit r/pt141info — PT-141 experience (opens in a new tab)Same-author route comparison: low and higher injections caused minor nausea with delayed desired effects; the later nasal spray was said to begin in 30–45 minutes without nausea and with strong sexual response. Nasal amount was not reported.Single anonymous account, unverified products, no calibrated nasal amount or assay, no blinded comparison and no duration beyond subjective onset.

Other context in this card

What people say 13

  • Needle avoidance: Primary modern practical reason people hunt nasal or compounded spray over SC autoinjector or insulin-syringe vials. forum
  • Clinic compounded spray claims: Some telehealth/compounding write-ups describe needle-free PRN use with timing similar to SC (~30–60+ min pre-activity); absorption is described as less predictable than injection when congestion or technique varies. forum
  • Responder split: Clear responders and non-responders within a few spaced exposures is a repeated community pattern for both routes; non-response is common. forum
  • Sparse modern nasal logs: Systematic outcome data for gray-market or home-mixed nasal are thinner than SC/Vyleesi or historical trial literature. forum
  • Not a PDE5 substitute: Mechanism is central desire/arousal signaling; men who only need blood-flow often still discuss PDE5s or stacks rather than melanocortin alone. forum
  • Historical ED — early IN PK/PD: Double-blind placebo-controlled evaluation (healthy men + mild–moderate ED) found statistically significant erectile responses vs placebo at nasal doses greater than ~7 mg; first erection onset often ~30 min; flushing and nausea were the top AEs. trial
  • IN PK (early male work): Mean Cmax and AUC rose dose-dependently; median Tmax ~0.50 h; mean t½ roughly ~1.85–2.09 h in those summaries. trial
  • Phase I-style dose ladder: Published overviews of early work describe placebo vs single IN doses around 4, 7, 10, and 20 mg bands in healthy men, and 7 or 20 mg in sildenafil-responsive ED cohorts — erectogenic signals strongest at the higher end. trial
  • Sildenafil non-responders (Safarinejad 2008): Randomized double-blind placebo-controlled salvage study — ~10 mg bremelanotide as intranasal spray, timed ~45 min to 2 h before stimulation; positive clinical response often cited ~33.5% (bremelanotide) vs ~8.5% (placebo). trial
  • Co-admin with sildenafil (Diamond 2005-style): Subtherapeutic/low IN PT-141 (classic design: 7.5 mg IN + 25 mg sildenafil) enhanced erectile activity on RigiScan vs sildenafil + nasal placebo during visual sexual stimulation windows; other exploratory arms used 7.5–10 mg IN with 50–100 mg sildenafil and reported multi-fold longer erectile activity duration in some summaries. trial
  • CNS desire framing (shared with SC): Subjective ‘want’ / mental arousal talk is the same melanocortin story as injectable PT-141 — nasal is delivery, not a different drug class. forum
  • SC desire evidence (not nasal): Phase 3 HSDD gains (FSFI desire domain, less distress) are SC Vyleesi data — do not treat unregulated nasal as having the same labeled evidence package. trial
  • Larger at-home ED program (AUA-era / ~726 men talk): On-demand nasal doses of 5, 7.5, 10, 12.5, or 15 mg for ~12 weeks, taken ~45 min before activity; doses ~7.5 mg and above commonly restated as showing IIEF improvements vs placebo, with dose-dependent framing. trial

Doses people talk about 13

  • Compounded per-spray talk: Often ~0.5–2 mg per spray / 1–2 sprays total; one telehealth script: 1 mg per spray, start one nostril ~45–60 min pre-activity, optional second spray other nostril if first tolerated, max ~2 mg/use, ≤1 use/24 h and ≤3×/week in that clinic’s instructions. forum
  • Titration talk (modern nasal): Start lower (one spray / lower mg) to probe nausea, flush, and BP before any second spray — mirrors SC start-low culture. forum
  • Uncertainty rule: If identity and delivered mg are unknown, historical trial numbers cannot be ‘copied’ safely — they describe controlled study formulations. forum
  • Modern clinic SC titration context (for comparison): Many off-label men’s clinics start ~1 mg SC, sweet spot often ~1–2 mg, and treat >~2 mg as where nausea becomes dose-limiting — this is SC culture, not historical 10 mg IN trial culture. forum
  • Framing: Ranges below mix historical controlled IN trials, modern compounding/clinic scripts, and forum talk — research/education only, not advice or a self-use protocol. forum
  • Critical split — trial-era IN vs modern compounded IN: Early ED programs used multi-milligram nasal loads (often ~5–20 mg); many modern clinic sprays advertise ~0.5–2 mg total per occasion. These are not interchangeable mass numbers and may not share absorption or formulation. trial
  • Historical nasal bands (male ED): Roughly mid-single-digit to ~15–20 mg IN on-demand explored; erectogenic significance often cited above ~7 mg in early controlled work. trial
  • Multi-dose ladder (large ED program talk): 5 / 7.5 / 10 / 12.5 / 15 mg IN arms with ~45 min lead-in; benefit signals restated for ≥7.5 mg bands vs placebo in secondary summaries. trial
  • High-exposure IN PK/alcohol study: Single 20 mg IN doses used in a Phase I-style ethanol co-admin design; authors described that IN exposure as on the order of ~1–2× the SC exposure range under development for Phase III — illustrates non-1:1 mg conversion across routes. trial
  • Combo study examples: 7.5 mg IN + 25 mg sildenafil (Diamond et al.); exploratory 7.5 or 10 mg IN with 50 or 100 mg sildenafil — enhanced erectile activity vs sildenafil alone in RigiScan designs. trial
  • Nasal ≠ SC milligram math: Bioavailability and Cmax variability differ by route; old nasal mg is not a 1:1 map to 1.75 mg SC Vyleesi. trial
  • Common restated on-demand trial figure: ~10 mg IN appears repeatedly (e.g. sildenafil-failure salvage RCT; mid-range of multi-dose Phase 2-style ladders). trial
  • Labeled SC reference (different route): Vyleesi 1.75 mg SC PRN; ≥45 min before activity; ≤1 dose/24 h; ≤8 doses/month; discontinue if no benefit by ~8 weeks — people borrow these caps as nasal caution even when product is unapproved. trial

How it may feel 8

  • First 15–45 min: Wait for onset; watch flush, nasal sting/drip, queasiness, and congestion — local nasal sensations can appear before any systemic ‘desire’ feel. forum
  • First 1–3 uses: Calibration for sides (especially nausea), personal timing, and whether the product/route does anything before judging benefit or escalating. forum
  • Intermittent pattern: Event-tied PRN — no continuous multi-week ‘loading cycle’ feel like some GH peptides. forum
  • Pre-dose planning: Historical trials often aimed ~45 min before activity; community spray talk commonly plans ~30–60+ min, sometimes waiting 10–20 min after a first spray before a second (clinic titration scripts). trial
  • ~30 min class signal (trial): Early IN work described first erection onset around ~30 min when erectogenic effects appeared. trial
  • Older hours 1–4 framing and conflicting newer reports: Earlier community notes describe several-hour same-day desire/arousal rather than a usual multi-day afterglow. One inspected user claimed 1.25 mg total and effects within 10 minutes that lasted about 20 minutes; another reported no effect at a nominal 2 mg, and a separate route-comparison user described 30–45-minute nasal onset without nausea. forum
  • Same-day side curve: Nausea and flush often front-loaded in the first 1–2 hours; SC label/clinical summaries put nausea onset often ≤1 h and duration ~2 h — communities reuse that curve for nasal caution talk even though route differs. trial
  • Nausea attenuates for some: SC trial narratives often show highest nausea after dose one, lower later; community nasal talk expects a similar ‘first-dose is worst’ pattern but not for everyone. trial

Cycles people discuss 7

  • PRN, not bodybuilding cycles: Event-tied sexual timing — not multi-week daily peptide load/maintain schedules. forum
  • Clinic spray frequency example: Some compounded programs state ≤3 uses/week in addition to the 24 h rule — a different weekly ceiling that can permit more than the SC label's eight monthly doses; it is not a stricter monthly limit or a validated nasal rule. forum
  • Stops on tolerability: Nausea, BP worry, nasal irritation/congestion, or cost end use more often than a planned ‘cycle end date.’ forum
  • Event planning pattern: Date-night / weekend PRN dominates; fixed daily nasal calendars are not the clinical or forum norm. forum
  • Daily cap borrowed from SC label: ≤1 dose per 24 hours is the standard caution people apply across routes because consecutive doses may stack BP effects and redosing efficacy is not established. trial
  • Monthly intensity caution: SC label ≤8 doses/month is often reused as a nasal frequency ceiling in clinic notes (hyperpigmentation and BP risk rise with denser use). trial
  • Trial-then-reassess: Handful of spaced PRN trials before any ongoing habit; SC label 8-week no-benefit stop rule is commonly borrowed as a decision point. trial

Timing 11

  • Nasal onset talk: Often aim ~30–60+ min pre-activity; spray technique, drip, and congestion shift perceived timing without proving systemic levels. forum
  • Effect vs plasma: Subjective desire/erectile windows may outlast simple half-life arithmetic — incompletely characterized for either route. forum
  • Local nasal confounders: Congestion, epistaxis risk talk, post-nasal drip, and uneven spray deposition can change feel without proving dose delivered. anecdote
  • IN Tmax (early male PK): Median ~0.50 h after intranasal administration in Diamond-era summaries. trial
  • IN half-life (early male PK): Mean t½ roughly ~1.85–2.09 h in those nasal studies — short, acute PRN pharmacology. trial
  • SC half-life (label, different route): Mean terminal ~2.7 h (about 1.9–4 h range) after subcutaneous Vyleesi. trial
  • SC peak (label): Plasma peak often ~1 h (median Tmax ~1.0 h) — communities sometimes reuse SC timing for spray lead-in guesses. trial
  • Bioavailability / variability problem (why SC won): Sponsor summaries stated nasal administration produced significant inter-subject variation in plasma levels plus BP rises in some patients — leading to discontinuation of nasal as first-line sexual-dysfunction development. trial
  • Exposure bridge note: A 20 mg IN dose was described in one Phase I ethanol study as producing exposure roughly comparable to ~1–2× the SC dose range under Phase III development — route conversion is approximate and study-specific. trial
  • BP/HR time course (SC label class data often reused): Transient BP up and HR down after dose; maximal mean rises on the order of ~+6 mmHg SBP / ~+3 mmHg DBP peaking ~2–4 h post-dose, HR down up to ~5 bpm, usually resolving toward baseline within ~12 h. trial
  • Ethanol co-admin note: Phase I-style work reported no clinically significant PK interaction between 20 mg IN BMT and ethanol in that design — not a green light for heavy drinking with melanocortin PRN use. trial

More on what it is 9

  • Why this card exists: Forums, compounding clinics, and telehealth still chase needle-free ‘nasal PT-141’ as an alternative to autoinjector or research vials — even though the commercial path abandoned nasal. forum
  • What it is: Bremelanotide (PT-141) is a cyclic heptapeptide melanocortin-receptor agonist; early human development used intranasal spray, later pivoted to subcutaneous injection (FDA-approved Vyleesi 1.75 mg SC for premenopausal HSDD). trial
  • Mechanism (same either route): Central MC4R/MC3R desire and arousal signaling in the brain — not PDE5-style penile blood-flow pharmacology. trial
  • Lineage: Developed from the Melanotan II research path after melanocortin analogs showed unexpected sexual-arousal effects; PT-141 is discussed as the desire-focused cousin rather than a tanning agent. trial
  • Approved path today: FDA SC autoinjector only for acquired, generalized premenopausal HSDD; there is no marketed FDA consumer nasal Vyleesi product. trial
  • Why nasal died clinically: Palatin/FDA-era history: BP increases in some nasal subjects plus large inter-subject plasma-level variation led to halt of nasal first-line development (~2007–2008) and a switch to SC for more consistent exposure with a more manageable CV profile in later work. trial
  • Evidence mix: Stronger controlled history for high-dose historical nasal ED trials + modern SC Phase 3 HSDD; modern compounded nasal outcome data are thinner and less standardized than SC/Vyleesi talk. trial
  • Two dose cultures to keep separate: Historical trial nasal was often mid-single-digit to ~15–20 mg IN; modern clinic compounded sprays often talk ~0.5–2 mg total per use — do not treat them as the same product. trial
  • Research-only framing: Nasal mg, spray counts, onset, and stack talk below are discussion/trial data — not dosing advice or a use protocol. forum

Stacks 11

  • Combo rationale: Complementary mechanisms; discussed when desire is low, PDE5 alone was incomplete, or both ‘want’ and hardness are goals. forum
  • Stack titration caution: Community often establishes melanocortin alone first at a low modern band, then adds a familiar PDE5 dose under medical guidance — additive BP/CV considerations matter. forum
  • vs Melanotan II (comparison more than stack): MT-II shares melanocortin ancestry with stronger tanning (MC1R) plus libido lore; PT-141 is framed as cleaner desire focus with less intentional pigmentation. Casual MT-II + PT-141 stacks are repeatedly flagged as redundant receptor load with additive nausea/BP/pigment risk. forum
  • Kisspeptin-10 adjacency: Niche threads compare or sequence kisspeptin (HPG-axis upstream) vs PT-141 (melanocortin desire) — different axes; hard to attribute when combined. forum
  • Oxytocin adjacency: Bonding/sexual research peptide sometimes co-listed in broad ‘sex peptide’ menus — mechanism not the same as bremelanotide. forum
  • Non-drug context: Sleep, relationship quality, alcohol, anxiety/depression meds, and untreated hypogonadism often dominate whether any PRN peptide feels useful. forum
  • + PDE5 inhibitors (sildenafil / tadalafil): Most discussed practical stack — central desire (melanocortin) + peripheral erection blood-flow (PDE5). Historical IN PT-141 + sildenafil co-admin trials support enhanced erectile activity vs PDE5 alone in controlled RigiScan designs. trial
  • Historical combo numbers people cite: 7.5 mg IN PT-141 + 25 mg sildenafil; exploratory 7.5–10 mg IN with 50–100 mg sildenafil — study designs, not DIY recipes. trial
  • Anti-nausea co-talk: Antiemetics (e.g. ondansetron class talk) around first doses because nausea is the top limiter; SC trials documented antiemetic use in a meaningful subset — not casual self-medication advice. trial
  • vs flibanserin (Addyi): Not a stack — daily oral serotonergic HSDD agent vs PRN melanocortin; people search both as female-desire options. trial
  • Oral naltrexone caution (SC label interaction people reuse): Bremelanotide can reduce systemic exposure of oral naltrexone products used for alcohol/opioid use disorder — avoid co-use per product labeling logic. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 17

  • Dose-dependent nausea lore (modern low-mg culture): Clinic write-ups often claim most men tolerate ~1 mg SC well, mild queasiness more common near ~2 mg, and higher bands become mood-killing — modern compounded nasal titration scripts echo start-low for the same reason. forum
  • Source / identity risk: Compounded or research nasal may be mislabeled, degraded, contaminated, or poorly absorbed; gray-market sprays lack the autoinjector quality system. forum
  • Nausea (top AE, all routes): Dominant adverse effect; SC HSDD programs ~40% at ≤8 doses/month intensity; historical nasal trials also flagged nausea prominently with flushing. trial
  • Nausea course (SC label data often applied as caution): Often starts within the first hour, lasts ~2 hours; highest after first dose, may fall on later doses for many; can be severe enough for antiemetics or discontinuation (~8% discontinued for nausea in SC trial tallies; ~13% used antiemetics in common summaries). trial
  • Flushing / warmth: Very common in both nasal and SC safety summaries (~20% facial flushing class figure on SC). trial
  • Headache / vomiting: Headache common (~11% class); vomiting less often (~5% class) but documented on SC safety lists. trial
  • Why nasal BP history matters: Increases in blood pressure in some nasally dosed patients, coupled with plasma-level variability, drove FDA-era clinical holds and sponsor discontinuation of nasal as first-line sexual-dysfunction therapy (~2007–2008). trial
  • SC still has BP warning: Even after the route switch, Vyleesi carries transient BP/HR warnings and frequency caps — SC is not ‘BP-free,’ just the path that continued development. trial
  • Nasal-local AEs: Congestion, irritation, drip, sneeze, cough, altered smell/taste talk — SC does not share these local effects. trial
  • Hyperpigmentation (melanocortin class): Focal darkening of face, gums, breasts reported with repeat exposure (~1% at labeled monthly intensity in Phase 3; higher risk with denser dosing and darker baseline skin); may not fully reverse — consider stop if pigmenting. trial
  • Absorption unpredictability: Congestion, technique, and formulation differences mean the same labeled ‘mg’ may not deliver the same exposure — this was a formal development concern, not only forum lore. trial
  • Not approved nasal: No FDA consumer nasal bremelanotide product — use outside Vyleesi’s labeled risk-management and indication is off-label or unregulated research talk. trial
  • Population / indication limits: Approved only for specific premenopausal HSDD SC use; not labeled for men, postmenopausal women, or recreational performance. trial
  • Oral drug interactions (label logic): May slow gastric emptying and affect some oral meds; oral naltrexone exposure reduction is a highlighted clinically relevant interaction. trial
  • Never risk-free: High AE rates even on pharma SC product; historical nasal BP issues plus modern product uncertainty compound risk for unregulated sprays. trial
  • BP up / HR down: Transient pressor effect and reflex HR reduction after dose — core safety theme; contraindicated framing for uncontrolled hypertension or known CVD on approved product. trial
  • Pregnancy / lactation: Not established as safe; stop and seek care framing applies if pregnancy occurs on labeled product. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →